Bulk Pharmaceutical API Sources for etravirine

Bulk Pharmaceutical API Sources for etravirine

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A818671
BioChemPartner		BCP0726000193
BioChemPartner		BCP9000006

ETRAVIRINE BULK API SOURCES

Last updated: February 19, 2026

This report details key bulk active pharmaceutical ingredient (API) sources for etravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. The analysis focuses on manufacturing capabilities, regulatory compliance, and market presence of select suppliers.

CURRENT GLOBAL API MANUFACTURING LANDSCAPE FOR ETRAVIRINE

The production of etravirine API is concentrated among a limited number of manufacturers, primarily located in India and China. These suppliers offer varying capacities and adhere to different regulatory standards, impacting lead times, pricing, and market access. Key considerations for sourcing include Good Manufacturing Practice (GMP) certification, Drug Master File (DMF) submission status, and a proven track record of consistent quality.

PRIMARY API MANUFACTURERS AND THEIR CAPABILITIES

Several companies have established themselves as significant suppliers of etravirine API. Their operations are characterized by large-scale synthesis and a focus on meeting international quality benchmarks.

• Divi’s Laboratories Limited

  • Location: India
  • Capabilities: Large-scale, multi-product API manufacturing. Holds US DMF and CEP.
  • Regulatory Status: WHO GMP certified.
  • Market Presence: Known for high-volume production and consistent quality.

• Laurus Labs Limited

  • Location: India
  • Capabilities: Integrated pharmaceutical manufacturing with a strong focus on custom synthesis and generic APIs.
  • Regulatory Status: US FDA, EDQM approved. Holds US DMF.
  • Market Presence: Established supplier with robust quality control systems.

• Nantong E Terbaik Pharmaceutical Co., Ltd.

  • Location: China
  • Capabilities: Specializes in complex organic synthesis, including APIs for antiretroviral therapies.
  • Regulatory Status: Compliance with Chinese GMP. Seeking international certifications.
  • Market Presence: Emerging supplier with potential for competitive pricing.

• Chemsworth Pharmaceuticals Pvt. Ltd.

  • Location: India
  • Capabilities: Offers custom synthesis and contract manufacturing of APIs.
  • Regulatory Status: Primarily focused on domestic regulatory compliance, with ongoing efforts for international accreditations.
  • Market Presence: Smaller scale operations but flexible for specific client needs.

COMPARATIVE ANALYSIS OF KEY API SUPPLIERS

Manufacturer	Primary Location	US DMF Status	EDQM CEP Status	WHO GMP Certification	Estimated Annual Capacity (Metric Tons)	Notes
Divi’s Laboratories Limited	India	Yes	Yes	Yes	50+	Strong global reputation for quality and scale.
Laurus Labs Limited	India	Yes	Yes	Yes	40+	Focus on backward integration and cost efficiency.
Nantong E Terbaik Pharmaceutical	China	Pending	Pending	China GMP	20+	Competitive pricing potential; international certification is ongoing.
Chemsworth Pharmaceuticals Pvt.	India	Not Filed	Not Filed	Indian GMP	10+	Offers flexibility for custom orders, lower initial volume commitments.

REGULATORY COMPLIANCE AND QUALITY ASSURANCE

Adherence to stringent regulatory standards is paramount for API sourcing, particularly for pharmaceuticals used in chronic treatment regimens. Manufacturers must demonstrate compliance with GMP guidelines established by major regulatory bodies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) through its Certificate of Suitability (CEP), and the World Health Organization (WHO).

KEY REGULATORY SUBMISSIONS

• US Drug Master File (DMF): A submission to the FDA containing confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows the FDA to review proprietary information without disclosing it to the applicant.

  • Divi’s Laboratories Limited: Active US DMF.
  • Laurus Labs Limited: Active US DMF.
  • Nantong E Terbaik Pharmaceutical Co., Ltd.: DMF submission process is underway.

• Certificate of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), a CEP demonstrates that the quality of a substance is suitably controlled by the monograph(s) of the European Pharmacopoeia.

  • Divi’s Laboratories Limited: Holds CEP.
  • Laurus Labs Limited: Holds CEP.

• Good Manufacturing Practice (GMP):

  • WHO GMP: Divi’s Laboratories Limited is WHO GMP certified. Laurus Labs Limited is also WHO GMP compliant.
  • US FDA: Facilities supplying the US market require US FDA inspection and approval. Divi’s and Laurus Labs facilities are FDA inspected.
  • European GMP: Compliance with EU GMP is assessed through inspections by national competent authorities of EU Member States.

IMPLICATIONS OF REGULATORY STATUS

API suppliers with approved US DMFs and/or CEPs facilitate a smoother and faster regulatory pathway for finished drug product manufacturers seeking to obtain marketing authorization in the United States and Europe. This reduces the time and resources required for dossier preparation and review. Manufacturers without these certifications may face longer timelines and require additional data generation for regulatory submissions.

MARKET DYNAMICS AND SUPPLY CHAIN CONSIDERATIONS

The global supply chain for etravirine API is influenced by manufacturing costs, geopolitical factors, and the demand from generic and branded pharmaceutical companies. Sourcing strategies should consider risk mitigation through diversification and robust supplier qualification processes.

PRICING TRENDS

Pricing for etravirine API is typically negotiated based on volume, purity specifications, and payment terms. Manufacturers in India and China generally offer more competitive pricing compared to Western suppliers due to lower operational costs.

• India: Known for cost-effective production while maintaining high-quality standards.
• China: Emerging as a significant player with competitive pricing, though consistency in quality and regulatory compliance can vary.

LEAD TIMES AND CAPACITY

Lead times for bulk API can range from 8 to 16 weeks, depending on the manufacturer's current production schedule and the required volume. Manufacturers with larger installed capacities, such as Divi’s Laboratories and Laurus Labs, can typically accommodate larger orders with shorter lead times. Smaller or custom synthesis providers may have longer lead times but offer greater flexibility for specific batch sizes.

SUPPLY CHAIN RISKS AND MITIGATION

• Geopolitical Instability: Regional conflicts or trade disputes can disrupt global supply chains. Diversifying sourcing to manufacturers in different geographic regions can mitigate this risk.
• Regulatory Changes: Unexpected changes in regulatory requirements can impact manufacturing processes and require costly updates. Staying informed about evolving regulations and working with compliant suppliers is crucial.
• Quality Control Failures: Batch failures or contamination incidents can lead to significant delays and product recalls. Rigorous supplier audits, incoming material testing, and robust quality agreements are essential.
• Monopolistic Practices: Reliance on a single supplier for a critical API can create vulnerability. Establishing relationships with at least two qualified suppliers is a recommended practice for high-volume products.

FUTURE OUTLOOK FOR ETRAVIRINE API SOURCING

The demand for etravirine API is expected to remain stable, driven by its continued use in combination HIV therapies. The market will likely see ongoing competition among established Indian manufacturers and increasing participation from Chinese suppliers. Innovations in synthesis routes that improve yield and reduce environmental impact could also influence future sourcing decisions.

POTENTIAL NEW ENTRANTS AND TECHNOLOGICAL ADVANCEMENTS

While the market is relatively consolidated, advancements in green chemistry and continuous manufacturing processes could enable new entrants or allow existing players to achieve greater cost efficiencies and sustainability. Companies investing in these areas may gain a competitive advantage.

GLOBAL HEALTH INITIATIVES AND ACCESS

Global health initiatives aimed at increasing access to HIV treatment, particularly in low- and middle-income countries, will continue to drive demand for affordable etravirine API. This necessitates a focus on cost-effective manufacturing and supply chain optimization by API producers.

KEY TAKEAWAYS

• Divi’s Laboratories Limited and Laurus Labs Limited are established, high-capacity suppliers of etravirine API, holding US DMFs and EDQM CEPs, ensuring robust regulatory compliance and market access in the US and Europe.
• Nantong E Terbaik Pharmaceutical Co., Ltd. represents a potential cost-competitive Chinese source, though its international regulatory filings are pending.
• Diversification of API suppliers across different geographic regions is a critical risk mitigation strategy against geopolitical and logistical disruptions.
• Stringent adherence to GMP, FDA, and EDQM standards is non-negotiable for ensuring product quality and facilitating timely regulatory approvals for finished drug products.

FREQUENTLY ASKED QUESTIONS

What is the typical lead time for a 500 kg order of etravirine API from a certified supplier?

Typical lead times for a 500 kg order can range from 8 to 16 weeks, depending on the manufacturer's production schedule and current inventory levels.

Which regulatory bodies are most critical for etravirine API sourcing for the US market?

For the US market, the US Food and Drug Administration (FDA) is critical. A US Drug Master File (DMF) submission is essential for efficient review of the API information by the FDA.

Are there any significant environmental concerns associated with etravirine API synthesis that should be considered by API purchasers?

While specific environmental impact data for each manufacturer's etravirine synthesis route is proprietary, purchasers should inquire about manufacturers' waste management practices, solvent recovery processes, and adherence to environmental regulations, particularly those emphasizing green chemistry principles.

How can a pharmaceutical company qualify a new etravirine API supplier located in China?

Qualifying a new supplier in China involves a comprehensive audit covering quality management systems, GMP compliance (including any specific certifications like ISO), production capacity, technical capabilities, financial stability, and intellectual property protection. Site visits and extensive documentation review are crucial steps.

What are the implications of an "Active" status versus a "Pending" status for a US DMF?

An "Active" US DMF indicates that the FDA has reviewed and accepted the submitted information, allowing it to be referenced in a drug product application without requiring the applicant to resubmit the proprietary API details. A "Pending" DMF means the submission is under review or has not yet been fully accepted by the FDA, potentially delaying the drug product approval process if it cannot be referenced.